Trials / Completed
CompletedNCT03463707
BP101 for Adults With Female Sexual Dysfunction
Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- Ivix LLX · Industry
- Sex
- Female
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD). Patients will be randomized in 1:1 ratio to either BP101 or placebo arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BP101 | Investigational product BP101, nasal spray |
| DRUG | Placebo | Placebo to Investigational product BP101, nasal spray |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2018-11-26
- Completion
- 2019-01-23
- First posted
- 2018-03-13
- Last updated
- 2020-02-11
Locations
20 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT03463707. Inclusion in this directory is not an endorsement.